Corrigendum to “The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure” [Placenta 36 (2015) 1138–1147] (Placenta (2015) 36(10) (1138–1147), (S0143400415300345), (10.1016/j.placenta.2015.08.007));The effect of maternal obesity on the expression and functionality of placental P-glycoprotein: Implications in the individualized transplacental digoxin treatment for fetal heart failure

Placenta

Volumn 36, Issue 10, 2015, Pages 1138-1147

  Wang, Chuan ^a,c   Li, Huaying ^b   Luo, Chunyan ^c   Li, Yifei ^a,c   Zhang, Yi ^a   Yun, Ding ^a,c   Mu, Dezhi ^a   Zhou, Kaiyu ^a   Hua, Yimin ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU WOMEN S AND CHILDREN S CENTRAL HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Digoxin; Fetal heart failure; Maternal obesity; P glycoprotein; Placenta

Indexed keywords

ABCB1A PROTEIN; ABCB1B PROTEIN; CHOLESTEROL; DIGOXIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PLACENTA PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARDIOTONIC AGENT;

ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETAL HEART FAILURE; FETUS MEMBRANE; GESTATIONAL AGE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; INSULIN BLOOD LEVEL; LIPID DIET; MATERNAL OBESITY; MATERNAL PLASMA; MOUSE; NONHUMAN; PLACENTAL TRANSFER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; C57BL MOUSE; CASE CONTROL STUDY; DISEASE MODEL; FETAL DISEASES; METABOLISM; OBESITY; PERSONALIZED MEDICINE; PLACENTA; PREGNANCY; PREGNANCY COMPLICATION; RANDOMIZATION;

ADULT; ANIMALS; CARDIOTONIC AGENTS; CASE-CONTROL STUDIES; DIGOXIN; DISEASE MODELS, ANIMAL; FEMALE; FETAL DISEASES; HEART FAILURE; HUMANS; MICE, INBRED C57BL; OBESITY; P-GLYCOPROTEIN; PLACENTA; PRECISION MEDICINE; PREGNANCY; PREGNANCY COMPLICATIONS; RANDOM ALLOCATION;

EID: 84944280056     PISSN: 01434004     EISSN: 15323102     Source Type: Journal    
DOI: 10.1016/j.placenta.2020.01.011     Document Type: Erratum

References (36)

1. T.H. Ojala, and L.K. Hornberger Fetal heart failure Front. Biosci. Sch. Ed. 2 2010 891 906
2. V. Thakur, J.C. Fouron, L. Mertens, and E.T. Jaeggi Diagnosis and management of fetal heart failure Can. J. Cardiol. 29 7 2013 759 767
3. M.T. Donofrio, A.J. Moon-Grady, L.K. Hornberger, J.A. Copel, M.S. Sklansky, A. Abuhamad, B.F. Cuneo, J.C. Huhta, R.A. Jonas, A. Krishnan, S. Lacey, W. Lee, E.C. Michelfelder Sr., G.R. Rempel, N.H. Silverman, T.L. Spray, J.F. Strasburger, W. Tworetzky, and J. Rychik Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American heart association Circulation 129 21 2014 2183 2242
4. S.A. Qasqas, C. McPherson, W.H. Frishman, and U. Elkayam Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation Cardiol. Rev. 12 4 2004 201 221
5. K. Zhou, R. Zhou, Q. Zhu, Y. Li, C. Wang, C. Wan, D. Mu, and Y. Hua Evaluation of therapeutic effect and cytokine change during transplacental digoxin treatment for fetal heart failure associated with fetal tachycardia, a case-control study Int. J. Cardiol. 169 4 2013 e62-4
6. K. Zhou, Y. Hua, Q. Zhu, H. Liu, S. Yang, R. Zhou, and N. Guo Transplacental digoxin therapy for fetal tachyarrhythmia with multiple evaluation systems J. Matern. Fetal Neonatal Med. 24 11 2011 1378 1383
7. F. Staud, L. Cerveny, and M. Ceckova Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure J. Drug Target 20 9 2012 736 763
8. M. Ceckova-Novotna, P. Pavek, and F. Staud P-glycoprotein in the placenta: expression, localization, regulation and function Reprod. Toxicol. 22 3 2006 400 410
9. J.D. Ma, S.M. Tsunoda, J.S. Bertino Jr., M. Trivedi, K.K. Beale, and A.N. Nafziger Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation Clin. Pharmacokinet. 49 4 2010 223 237
10. J.W. Smit, M.T. Huisman, O. van Tellingen, H.R. Wiltshire, and A.H. Schinkel Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure J. Clin. Invest 104 10 1999 1441 1447
11. P.S. Soo, J. Hiscock, K.J. Botting, C.T. Roberts, A.K. Davey, and J.L. Morrison Maternal undernutrition reduces P-glycoprotein in guinea pig placenta and developing brain in late gestation Reprod. Toxicol. 33 3 2012 374 381
12. G.J. Anger, A.M. Cressman, and M. Piquette-Miller Expression of ABC Efflux transporters in placenta from women with insulin-managed diabetes PLoS One 7 4 2012 e35027
13. C.W. Mason, I.A. Buhimschi, C.S. Buhimschi, Y. Dong, C.P. Weiner, and P.W. Swaan ATP-binding cassette transporter expression in human placenta as a function of pregnancy condition Drug Metab. Dispos. 39 6 2011 1000 1007
14. C. Wang, H. Li, K. Zhou, C. Luo, Y. Li, L. Xie, and Y. Hua Sodium tanshinone IIA sulfonate and sodium danshensu open the placental barrier through down-regulation of placental P-glycoprotein in mice: Implications in the transplacental digoxin treatment for fetal heart failure Int. J. Cardiol. 176 3 2014 1331 1333
15. C. Wang, L. Xie, K. Zhou, Y. Zhan, Y. Li, H. Li, L. Qiao, F. Wang, and Y. Hua Increased risk for congenital heart defects in children carrying the ABCB1 Gene C3435T polymorphism and maternal periconceptional toxicants exposure PLoS One 8 7 2013 e68807
16. M. Bhuiyan, S. Petropoulos, W. Gibb, and S.G. Matthews Sertraline alters multidrug resistance phosphoglycoprotein activity in the mouse placenta and fetal blood-brain barrier Reprod. Sci. 19 4 2012 407 415
17. G.M. Kalabis, A. Kostaki, M.H. Andrews, S. Petropoulos, W. Gibb, and S.G. Matthews Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: fetal protection Biol. Reprod. 73 4 2005 591 597
18. P. Gordon-Larsen, H. Wang, and B.M. Popkin Overweight dynamics in Chinese children and adults Obes. Rev. Off. J. Int. Assoc. Study Obes. 15 Suppl 1 2014 37 48
19. D. Galliano, and J. Bellver Female obesity: short- and long-term consequences on the offspring Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol. 29 7 2013 626 631
20. S.S. Huda, L.E. Brodie, and N. Sattar Obesity in pregnancy: prevalence and metabolic consequences Semin. Fetal Neonatal Med. 15 2 2010 70 76
21. G.J. Anger, and M. Piquette-Miller Mechanisms of reduced maternal and fetal lopinavir exposure in a rat model of gestational diabetes Drug Metab. Dispos. 39 10 2011 1850 1859
22. M. Iqbal, H.L. Ho, S. Petropoulos, V.G. Moisiadis, W. Gibb, and S.G. Matthews Pro-inflammatory cytokine regulation of P-glycoprotein in the developing blood-brain barrier PLoS One 7 8 2012 e43022
23. D.A. Evseenko, J.W. Paxton, and J.A. Keelan Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors Drug Metab. Dispos. 35 4 2007 595 601
24. M. Sukhai, A. Yong, A. Pak, and M. Piquette-Miller Decreased expression of P-glycoprotein in interleukin-1beta and interleukin-6 treated rat hepatocytes Inflamm. Res. Off. J. Eur. Histamine Res. Soc. [et al] 50 7 2001 362 370
25. Y. Liu, G. Tong, W. Tong, L. Lu, and X. Qin Can body mass index, waist circumference, waist-hip ratio and waist-height ratio predict the presence of multiple metabolic risk factors in Chinese subjects? BMC Public Health 11 2011 35
26. W.F. Wang, S.M. Li, G.P. Ren, W. Zheng, Y.J. Lu, Y.H. Yu, W.J. Xu, T.H. Li, L.H. Zhou, Y. Liu, and D.S. Li Recombinant murine fibroblast growth factor 21 ameliorates obesity-related inflammation in monosodium glutamate-induced obesity rats Endocrine 49 1 2015 119 129
27. C. Hurault-Delarue, I. Lacroix, S. Vidal, J.L. Montastruc, and C. Damase-Michel Drugs in pregnancy: study in the EFEMERIS database (2004 to 2008) Gynecol Obstet Fertil 39 10 2011 554 558
28. R. Blanco, A. Colombo, and J. Suazo Maternal obesity is a risk factor for orofacial clefts: a meta-analysis Br. J. Oral Maxillofac. Surg. 2015 June 11 (Epub ahead of print)
29. J.L. Mills, J. Troendle, M.R. Conley, T. Carter, and C.M. Druschel Maternal obesity and congenital heart defects: a population-based study Am J Clin Nutr 91 6 2010 1543 1549
30. G.R. Lankas, L.D. Wise, M.E. Cartwright, T. Pippert, and D.R. Umbenhauer Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice Reprod Toxicol 12 4 1998 457 463
31. A. Omoumi, Z. Wang, V. Yeow, Y.H. Wu-Chou, P.K. Chen, I. Ruczinski, J. Cheng, F.S. Cheah, C.G. Lee, T.H. Beaty, and S.S. Chong Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations Eur. J. Hum. Genet. 21 12 2013 1436 1441
32. S.A. Obermann-Borst, A. Isaacs, Z. Younes, R.H. van Schaik, I.P. van der Heiden, C.M. van Duyn, E.A. Steegers, and R.P. Steegers-Theunissen General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect Am J Obstet Gynecol 204(3) 236 2011 e1 8
33. V. Petrovic, and M. Piquette-Miller Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats Drug Metab Dispos 38 10 2010 1760 1766
34. V. Petrovic, J.H. Wang, and M. Piquette-Miller Effect of endotoxin on the expression of placental drug transporters and glyburide disposition in pregnant rats Drug Metab Dispos 36 9 2008 1944 1950
35. P.M. Coan, A.C. Ferguson-Smith, and G.J. Burton Developmental dynamics of the definitive mouse placenta assessed by stereology Biol Reprod 70 6 2004 1806 1813
36. E.D. Watson, and J.C. Cross Development of structures and transport functions in the mouse placenta Physiology (Bethesda, Md) 20 2005 180 193